Study of Talazoparib and Enzalutamide for Prostate Cancer
Author Information
Author(s): Nobuaki Matsubara, Hideaki Miyake, Hiroji Uemura, Atsushi Mizokami, Hiroaki Kikukawa, Takeo Kosaka, Kazuo Nishimura, Motonobu Nakamura, Kazuki Kobayashi, Atsushi Komaru, Yuko Mori, Shigeyuki Toyoizumi, Natsuki Hori, Yoshiko Umeyama, Hirotsugu Uemura
Primary Institution: National Cancer Center Hospital East Kashiwa Japan
Hypothesis
Does the combination of talazoparib and enzalutamide improve treatment outcomes in Japanese patients with metastatic castration-resistant prostate cancer?
Conclusion
The combination of talazoparib and enzalutamide showed consistent efficacy and safety in Japanese patients compared to the overall population.
Supporting Evidence
- The combination improved radiographic progression-free survival compared to placebo.
- Anemia was the most common adverse event.
- Safety profiles were similar between Japanese and overall populations.
- Objective response rate was 55% in the talazoparib arm.
- Median rPFS was not reached in either treatment arm for the Japanese subgroup.
- Patients with BRCA1/2 alterations showed significant benefits.
- Pharmacokinetics were comparable across different populations.
- Overall survival data remain immature.
Takeaway
This study looked at a new medicine for prostate cancer and found it works well for Japanese patients, just like it does for others.
Methodology
The study was a randomized, double-blind, phase 3 trial comparing talazoparib plus enzalutamide to placebo plus enzalutamide in Japanese patients with mCRPC.
Potential Biases
Potential biases due to the exploratory nature of the subgroup analysis.
Limitations
The analysis was exploratory and lacked formal statistical power.
Participant Demographics
The study included 116 Japanese patients with a median age of 72 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI, 0.45–1.75
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website